Alnylam reported second-quarter 2026 total revenues of $1.291 billion and GAAP net income of $164.5 million, driven by strong product sales. Total net product revenues were $1.172 billion, with AMVUTTRA accounting for $1.012 billion of TTR net product revenues. The company updated full-year 2026 TTR guidance lower to $4.2B–$4.5B while reiterating Rare product guidance and maintaining investment in R&D and commercial launch activities.

Financial Highlights

  • Total revenues for Q2 2026: $1,290,948 thousand (67% increase vs. Q2 2025).
  • Total net product revenues for Q2 2026: $1,172,109 thousand (74% increase vs. Q2 2025).
  • Total TTR net product revenues (AMVUTTRA & ONPATTRO) for Q2 2026: $1,030,223 thousand (89% increase vs. Q2 2025); AMVUTTRA net product revenues: $1,011,762 thousand (106% increase).
  • GAAP Income from operations: $231,441 thousand; GAAP Net income: $164,494 thousand for Q2 2026 (compared with GAAP net loss of $(72,228) thousand in Q2 2025).
  • Non-GAAP diluted net income per share: $1.84 for Q2 2026 (Non-GAAP net income $251,801 thousand).

Business Highlights

  • AMVUTTRA continues global expansion and momentum: recent launch in Spain and exclusive commercial agreement for mainland China and Macao with BeOne Medicines.
  • Presented HELIOS-B data at Heart Failure 2026 showing consistent clinical benefit of vutrisiran across patient subgroups and pooled safety analyses supporting RNAi therapies' safety profile.
  • Announced DETECT-ATTR collaboration with a large California health system to evaluate an AI-enabled echocardiography screening approach for cardiac amyloidosis to improve case identification and diagnosis.
  • Pipeline progress: initiated Phase 2 trials of ALN-6400 (von Willebrand disease) and mivelsiran (Down syndrome–associated Alzheimer’s disease); completed enrollment in cAPPricorn-1 Phase 2 for CAA; Phase 1 ALN-6222 initiated in obesity.
  • Strategic technology and data collaborations: partnership with Inceptive to accelerate RNAi discovery using foundation models, expanded Komodo Health partnership to scale commercial intelligence, and ongoing AI integration across functions.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.